Printer Friendly

NEUROCRINE BIOSCIENCES NAMES PAUL W. HAWRAN VICE PRESIDENT AND CHIEF FINANCIAL OFFICER

 LA JOLLA, Calif., May 19 /PRNewswire/ -- Neurocrine Biosciences Inc., a La Jolla-based biopharmaceutical company, announced the appointment of Paul W. Hawran as vice president and chief financial officer. Formerly vice president and treasurer of SmithKline Beecham Corp. (the U.S. subsidiary of SmithKline Beecham plc.), Hawran has more than 17 years of financial experience, most recently including eight years in various financial capacities within the pharmaceutical industry, according to Gary Lyons, company president and chief executive officer.
 "Paul brings to Neurocrine a solid background in finance," Lyons said. "Specifically, Paul's experience in the areas of corporate finance, financial planning, treasury, tax and accounting, provides a strong basis upon which to build the financial success of Neurocrine. At SmithKline, Paul participated in the formation of SmithKline Beckman and Beecham in 1989, one of the most successful mergers to date, and in the ensuing period completing over $1 billion in public and private debt, leasing and equity issues."
 Hawran joined Beecham in 1984 as assistant treasurer-Corporate Finance, responsible for merger and acquisition, financing and corporate insurance activities. In 1989, he was promoted to vice president and deputy treasurer of SmithKline Beecham Corp. and was responsible for reorganizing the company's regional corporate finance and treasury activities.
 Prior to SmithKline Beecham, Hawran held a variety of financial positions at Warner Communications Inc. (now Time-Warner) from 1980 to 1984 where he was promoted to director of corporate finance. There he was involved with worldwide corporate finance, budgeting and forecasting.
 Hawran received a bachelor's degree in Finance from St. John's University (1975) and a master's degree in Taxation from Seton Hall University (1989). He is a Certified Public Accountant in the Commonwealth of Pennsylvania and is a member of the American Institute of Certified Public Accountants, Pennsylvania Institute of Certified Public Accountants and the Financial Executive Institute.
 Neurocrine Biosciences Inc. was organized in January 1992 to develop novel pharmaceutical products to treat diseases resulting from aging- and stress-related disregulation of the nervous, immune and endocrine systems. The company has raised initial venture capital financing from Avalon Medical Partners, D. Blech & Co. and Kleiner Perkins Caufield and Byers.
 -0- 5/19/93
 /CONTACT: Linda Seaton of Keatinge/Seaton Communications, 619-625-2100, for Neurocrine Biosciences/


CO: Neurocrine Biosciences Inc. ST: California IN: MTC SU: PER

LS-MS -- SD003 -- 0149 05/19/93 09:15 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 19, 1993
Words:385
Previous Article:SUN NAMES VICE PRESIDENTS
Next Article:COUNTY-WIDE CLASS ACTION CERTIFIED IN POLYBUTYLENE PLASTIC PLUMBING CASE
Topics:


Related Articles
NEUROCRINE BIOSCIENCES, INC. COMPLETES PUBLIC OFFERING OF 3,500,000 SHARES OF COMMON STOCK
NEUROCRINE BIOSCIENCES ANNOUNCES SECOND QUARTER FINANCIAL RESULTS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters